Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. Issue 4 (4th April 2023)

• Record Type: Journal Article
• Authors: Tun, Aung M.; Wang, Yucai; Matin, Aasiya; Inwards, David J.; Habermann, Thomas M.; Micallef, Ivana; Johnston, Patrick B.; Porrata, Luis; Paludo, Jonas; Bisneto, Jose Villasboas; Rosenthal, Allison; Tun, Han W.; Cerhan, James R.; Witzig, Thomas E.; Nowakowski, Grzegorz S.; Ansell, Stephen M.
• Is Part Of: HemaSphere. Volume 7:Issue 4(2023)
• Page Start: e869
• Publication Date: 2023-04-04
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/HS9.0000000000000869
• Languages: English
• ISSNs: 2572-9241

Abstract

Abstract : Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse, in comparison with conventional therapy, is less known due to the lack of randomized controlled trials. Clinical characteristics and outcomes of 115 patients with relapse (or progression) after ASCT are studied. After a median follow-up of 8.59 years from post-ASCT relapse, the median progression-free survival (PFS) and overall survival (OS) were 0.91 and 5.07 years, respectively. Median lines of therapy after post-ASCT relapse was 2 (range, 1–12). The median PFS was not reached (NR) versus 1.11 versus 0.50 versus 0.85 versus 0.78 years ( P = 0.006) and OS was NR versus 7.60 versus 3.08 versus 3.51 versus 3.17 years ( P = 0.28) in patients first treated with ICIs versus BV versus investigational agents versus chemotherapy versus radiation therapy (RT). First-line treatment with novel agents (ie, ICIs and BV) was associated with superior outcomes compared with investigational agents and chemotherapy/RT with a median PFS of 1.65 versus 0.50 versus 0.79 years ( P = 0.003) and a median OS of 7.60 versus 3.08 versus 3.32 years ( P = 0.08). Regardless of lines of therapy, the treatment with ICIs had the most favorable outcome with a median PFS and OS of 3.98 and NR years, respectively. Allogeneic stem cell transplant (allo-SCT) was done in 23 patients (20%), and the median post-allo-SCT PFS and OS were 1.31 and 2.35 years, respectively. In conclusion, survival following post-ASCT relapse improves significantly when patients receive novel agents. Abstract :